Ligand Pharmaceuticals Inc (LGND): Total Liabilities
$543.42M
As of 2025-12-31
$1.22B
As of 2026-06-30
+48.7%
3-year compound annual growth
-3.6%
5-year compound annual growth
+9.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $543.42M | +388.1% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $111.33M | +29.0% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $86.30M | -47.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $165.18M | -65.3% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $476.43M | -27.0% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $652.76M | -10.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $727.68M | +4.0% | 2021-02-24, Balance as of period end |
| 2018-12-31 | $699.89M | +177.3% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $252.37M | +9.4% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $230.73M | +2.0% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $226.15M | -3.2% | 2017-02-28, Balance as of period end |
| 2014-12-31 | $233.62M | +324.0% | 2016-11-14, Balance as of period end |
| 2013-12-31 | $55.10M | -29.2% | 2015-02-23, Balance as of period end |
| 2012-12-31 | $77.78M | -25.3% | 2014-12-12, Balance as of period end |
| 2011-12-31 | $104.05M | +44.4% | 2013-03-14, Balance as of period end |
| 2010-12-31 | $72.06M | n/a | 2012-11-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
Compare LGND, VREOF, HROW, ARVN side by side · Screen every company in Pharmaceutical Preparations ↗